CPC A61K 35/17 (2013.01) [A61K 31/365 (2013.01); A61K 39/39558 (2013.01); A61P 35/02 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 2317/34 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01)] | 20 Claims |
1. A Chimeric Antigen Receptor (CAR) specific for CD22 (Anti-CD22 CAR) comprising:
i) at least one extracellular domain comprising an antigen binding domain specific for CD22, and a hinge domain comprising an FcRIIIα, a CD8α, an IgG1, an IgG4, or a PD1 hinge;
ii) a transmembrane domain;
iii) an intracellular signaling domain comprising a CD3zeta signaling domain comprising an amino acid sequence having at least 95% identity with SEQ ID NO: 9; and
iv) at least one monoclonal antibody (mAb)-specific epitope(s) selected from the following sequences: CPYSNPSLC (SEQ ID NO: 91), NSELLSLINDMPITNDQKKLMSNN (SEQ ID NO: 114), CQFDLSTRRLKC (SEQ ID NO: 115), CQYNLSSRALKC (SEQ ID NO: 116), CVWQRWQKSYVC (SEQ ID NO: 117), SFVLNWYRMSPSNQTDKLAAFPEDR (SEQ ID NO: 119), SGTYLCGAISLAPKAQIKE (SEQ ID NO: 120), ELPTQGTFSNVSTNVSPAKPTTTA (SEQ ID NO: 92), and GQNDTSQTSSPS (SEQ ID NO: 121);
wherein said antigen binding domain specific for CD22 comprises a single chain variable fragment (scFv) specific for CD22, said scFv comprising a heavy chain variable (VH) region and a light chain variable (VL) region comprising one of the following combinations of sequences, respectively:
SEQ ID NO: 71 and SEQ ID NO: 72; SEQ ID NO: 73 and SEQ ID NO: 74; SEQ ID NO: 75 and SEQ ID NO: 76; SEQ ID NO: 77 and SEQ ID NO: 78; SEQ ID NO: 79 and SEQ ID NO: 80; SEQ ID NO: 81 and SEQ ID NO: 82; SEQ ID NO: 83 and SEQ ID NO: 84; SEQ ID NO: 85 and SEQ ID NO: 86; SEQ ID NO: 87 and SEQ ID NO: 88; or SEQ ID NO: 89 and SEQ ID NO: 90.
|